| Vol. 6.09 – 11 March, 2022 |
| |
|
|
| Investigators found that the hepatic subcellular organization of the endoplasmic reticulum architecture were highly dynamic, integrated with the metabolic state and critical for adaptive homeostasis and tissue health. [Nature] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists identified a proinflammatory hepatocyte subpopulation that developed primarily from periportal hepatocytes and to a lesser extent from pericentral hepatocytes and played key immunoregulatory roles in endotoxemia. [Journal of Hepatology] |
|
|
|
| Whole-genome sequencing revealed that circ-ZEB1 and PIK3CA were highly expressed in HCC tissues, whereas miR-199a-3p was significantly downregulated in HCC. [Molecular Cancer] |
|
|
|
| The authors showed that hepatocyte Kruppel-like factor 15 (KLF15) controlled plasma corticosteroid transport and inflammatory responses through direct transcriptional activation of Serpina6, which encoded corticosteroid-binding globulin. [Science Advances] |
|
|
|
| Researchers found that deficiency of Huwe1 in mice hepatocytes exacerbated ischemia-reperfusion injury and CCl4-induced liver injury with more ferroptosis occurrence, and that suppression of Huwe1 enhanced cellular sensitivity to ferroptosis in primary hepatocytes and mouse embryonic fibroblasts. [Cell Death & Differentiation] |
|
|
|
| Investigators showed that steroid receptor coactivator steroid receptor coactivator 3 coactivated X-box-binding protein-1 transcription and regulated hepatic 12 hour cistrome and gene rhythmicity. [Cell Reports] |
|
|
|
| Scientists discovered that the Notch1-c-myc-VCAM1 signaling axis initiated liver progenitor cell-driven hepatocarcinogenesis and metastasis, providing a preclinical model for HCC study. [Oncogene] |
|
|
|
| Researchers investigated the role of hepatic Sestrin2 in cholestatic liver injury and its underlying mechanisms using in vivo and in vitro approaches. [Experimental and Molecular Medicine] |
|
|
|
| RNA 3’-terminal phosphate cyclase-like protein (RCL1) expression was commonly down-regulated in HCC. The lower expression of RCL1 was associated with higher tumor stage, higher AFP level, vascular invasion, and poor prognosis. [Cancer Cell International] |
|
|
|
| Scientists presented the significant role of a novel signaling axis comprising long non-coding RNA maternally expressed gene 3 (MEG3), enhancer of zeste homolog 2 (EZH2), and sirtuin 6 (SIRT6) in controlling lipid accumulation, inflammation, and the progression of nonalcoholic fatty liver disease. [Cell Death Discovery] |
|
|
|
| The authors investigated the expression pattern, clinical prognosis, tumor biological functions, and molecular mechanisms of WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) in intrahepatic cholangiocarcinoma. [Cell Death Discovery] |
|
|
|
| Researchers investigated the inhibitory effects and underlying governing mechanism of clitorin in a western diet-induced hepatic steatosis mouse model, and in oleic acid-stimulated HepG2 cells. [Scientific Reports] |
|
|
|
| Scientists utilized the strategy of iterative gene pairing to construct a tumor-specific immune-related long intergenic noncoding RNA (lincRNA) pairs signature, which did not require specific expression levels, as an indicator of patient outcomes. [Scientific Reports] |
|
|
|
|
| Exploiting mutational signatures to retrospectively understand hepatobiliary carcinogenesis could advance preventative management of these aggressive tumors as well as potentially predict treatment response and guide the development of therapies targeting tumour evolution. [Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| Investigators summarize the preclinical data obtained in animal models treated with mRNA as a therapeutic agent and discuss the different gene editing strategies applied to the treatment of liver diseases, highlighting both their therapeutic efficacy as well as safety concerns. [Hepatology] |
|
|
|
| The authors appraise the existing literature and current clinical trial landscape of neoadjuvant therapies in HCC. [Clinical Cancer Research] |
|
|
|
|
| Inventiva announced that the US FDA has concluded that its lead drug candidate lanifibranor and the SGLT2 inhibitor empagliflozin1 in patients with type 2 diabetes (T2D) and non-cirrhotic non-alcoholic steatohepatitis (NASH) may proceed. [Inventiva] |
|
|
|
|
| Apr 27 – May 1, 2022 Riviera Maya, Mexico |
|
|
|
|
|
| Gilead Sciences – Foster City, California, United States |
|
|
|
| Amsterdam UMC – Amsterdam, Netherlands |
|
|
|
| NIH National Heart, Lung, and Blood Institute – Bethesda, Maryland, United States |
|
|
|
| Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| Columbia University – New York, New York, United States |
|
|
|
|